For the 11,000+ people
who have been treated with SPINRAZA worldwide,*
victories are personal.

*Based on commercial patients, early access patients, and clinical trial participants through December 2020.

Discover SPINRAZA: the first FDA-approved
treatment for SMA

7+ years

Safety and efficacy
evaluated
in the longest
clinical trial in
SMA to date

3x/year

SPINRAZA is directly delivered to

the central nervous system (CNS)
where
motor neuron loss begins.
After 4
initial loading doses,
SPINRAZA is
given 3 times a year.

From 3 days to 80 years old‡§

There’s someone from almost every
age group who has been treated
with SPINRAZA.

Includes clinical trial patients.

Clinical studies of SPINRAZA included patients from 3 days
to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether
they respond differently from younger patients.

§Based on commercial patients in the US (including Puerto
Rico) through December 2020.

Demonstrated efficacy in people with early- and later-onset SMA

Safety & side effects

The most common side effects of
SPINRAZA include lower respiratory
infection, fever, constipation, headache,
vomiting, back pain, and post-lumbar
puncture syndrome. These are not all of
the possible side effects of SPINRAZA.

How SPINRAZA works

SPINRAZA targets an underlying cause of muscle weakness in SMA.